People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Novo Nordisk urges customers to purchase medications solely from authorized pharmacies with valid prescriptions after a theft ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity and success of its GLP-1 therapies — Mounjaro for diabetes and Zepbound for ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

Certain batches of injectable medicines, including insulin and weight-loss drugs, were reported stolen in transit. Experts ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...